List of basic medicines: After preliminary selection, the catalogue includes 756 kinds of medicines, including 430 kinds of western medicines and 326 kinds of Chinese medicines; manufacturer's choice: take 3-5 years as a stage, and the province or city as a unit determines fixed-point manufacturers to purchase centrally; Mandatory provisions: Community health service centers (stations), township hospitals and other primary health care institutions should all be used, and other types of medical institutions should use it as the preferred drug and determine the proportion of use.
First, the number of drugs entering the catalog is greatly reduced. There are too many basic medicines, which is not conducive to doctors' rational use of medicines and basic medicines. The types of essential drugs recommended by the WTO to countries around the world and the practice of the international community show that there are about 200 to 300 basic drugs. China's most recent revised list of essential medicines contains 2,033 drugs, far exceeding the international level. The number of basic drug listings has been significantly reduced, and follow-up may be screened again, and the number is expected to decrease further.
Second, to promote the generalization of pharmaceutical production enterprises. The selection criteria for fixed-point manufacturers are not yet clarified, but due to the independent determination of manufacturers by provinces and municipalities, large-scale state-owned enterprises in the region are expected to benefit from the tilt of the policy as candidates; due to the principle of meagre pricing and government subsidies, fixed-point production enterprises may eventually It is to maintain a meager profit. Under such a background, the living environment of non-determined small-scale enterprises will deteriorate, and it can be expected that general pharmaceutical production enterprises will be concentrated and scaled.
Third, distribution companies will use this to establish a regional advantage. The state implements a "zero-judgment rate" policy, and destined for delivery will also be a meager profit. However, like the production companies, the most important thing is that the distribution companies can use this to achieve comprehensive coverage of provincial and municipal medical networks and establish an advantage within the region. It can be expected that once this distribution network is established, its low price and comprehensive coverage will exert tremendous pressure on competitors, which will undoubtedly have greater value for distribution companies.
Fourth, regional leading companies may be affected. In general, policies may centralize and scale the pharmaceutical industry and business in the region. Therefore, there are more opportunities for large-scale regional pharmaceutical and commercial companies. For these companies, short-term earnings are limited, and their value is more manifested after the scale of the company. Especially for commercial enterprises, the value of the network after the scale may be more obvious.
Leading industrial and commercial companies in all regions are worth paying attention to, raw materials and industrial enterprises, such as Qianjiang Biochemical, North China Pharmaceuticals, Baiyunshan, etc., and commercial enterprises such as Shanghai Pharmaceuticals, Accord Pharmaceutical, and East China Pharmaceutical.
First, the number of drugs entering the catalog is greatly reduced. There are too many basic medicines, which is not conducive to doctors' rational use of medicines and basic medicines. The types of essential drugs recommended by the WTO to countries around the world and the practice of the international community show that there are about 200 to 300 basic drugs. China's most recent revised list of essential medicines contains 2,033 drugs, far exceeding the international level. The number of basic drug listings has been significantly reduced, and follow-up may be screened again, and the number is expected to decrease further.
Second, to promote the generalization of pharmaceutical production enterprises. The selection criteria for fixed-point manufacturers are not yet clarified, but due to the independent determination of manufacturers by provinces and municipalities, large-scale state-owned enterprises in the region are expected to benefit from the tilt of the policy as candidates; due to the principle of meagre pricing and government subsidies, fixed-point production enterprises may eventually It is to maintain a meager profit. Under such a background, the living environment of non-determined small-scale enterprises will deteriorate, and it can be expected that general pharmaceutical production enterprises will be concentrated and scaled.
Third, distribution companies will use this to establish a regional advantage. The state implements a "zero-judgment rate" policy, and destined for delivery will also be a meager profit. However, like the production companies, the most important thing is that the distribution companies can use this to achieve comprehensive coverage of provincial and municipal medical networks and establish an advantage within the region. It can be expected that once this distribution network is established, its low price and comprehensive coverage will exert tremendous pressure on competitors, which will undoubtedly have greater value for distribution companies.
Fourth, regional leading companies may be affected. In general, policies may centralize and scale the pharmaceutical industry and business in the region. Therefore, there are more opportunities for large-scale regional pharmaceutical and commercial companies. For these companies, short-term earnings are limited, and their value is more manifested after the scale of the company. Especially for commercial enterprises, the value of the network after the scale may be more obvious.
Leading industrial and commercial companies in all regions are worth paying attention to, raw materials and industrial enterprises, such as Qianjiang Biochemical, North China Pharmaceuticals, Baiyunshan, etc., and commercial enterprises such as Shanghai Pharmaceuticals, Accord Pharmaceutical, and East China Pharmaceutical.
When you tear off the label, the material will show " VOID" mark on the surface. It is kind of tamper evident way.Our silver or white polyester VOID labels, also known as Warranty Labels, feature a tamper-evident surface that leaves a "VOID" pattern on the label and the surface when the label is lifted. This tamper evident seal is great for use on electronic equipment, rentals, or any other items when you need to prevent undetected access. These void labels cannot be switched to another piece of equipment without detection. A resin ribbon is required for printing on the VOID labels.
Void Hologram Label Sticker,Void Hologram Sticker,Void Hologram Label,Void Hologram Label Stickers
Shenzhen Tuteng Anti-Counterfeiting Co., Ltd. , https://www.holographicsticers.com